AC
EBS icon

Aristeia Capital’s Emergent Biosolutions EBS Stock Holding History

Aristeia Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,949
Closed -$345K – 728
2025
Q4 		$345K Buy
+27,949
New +$299K 0.01% 373
2025
Q3 		– Sell
-149,697
Closed -$955K – 561
2025
Q2 		$955K Buy
+149,697
New +$857K 0.03% 168
2025
Q1 		– Sell
-40,171
Closed -$384K – 456
2024
Q4 		$384K Buy
+40,171
New +$369K 0.01% 219
2024
Q3 		– Sell
-94,163
Closed -$642K – 399
2024
Q2 		$642K Sell
94,163
-50,625
-35% -$218K 0.01% 121
2024
Q1 		$366K Buy
+144,788
New +$326K 0.01% 133

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Aristeia Capital's EBS Position: Q1 2026 in Review

Aristeia Capital sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 27,949 shares — an estimated $345K sold.

Aristeia Capital first reported a position in EBS in Q1 2024 and held it in 5 quarters. The position peaked at $955K in Q2 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Aristeia Capital reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Aristeia Capital sold 27,949 Emergent Biosolutions shares in Q1 2026, an estimated $345K.
  • Aristeia Capital first reported a position in Emergent Biosolutions in Q1 2024 and held it in 5 quarters.
  • Aristeia Capital's Emergent Biosolutions position peaked at $955K in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Aristeia Capital's 13F filing for Q1 2026, filed 15 May 2026.